Sotagliflozin (Lexicon/Sanofi) is an orally administered drug currently being investigated for the treatment of type 1 and type 2 diabetes. It is a dual inhibitor of the sodium-glucose cotransporter-1 (SGLT-1) and SGLT-2 transporters. Inhibiting SGLT-2 prevents glucose reabsorption within the proximal convoluted tubule of the kidney. This results in urinary glucose excretion and reduced plasma glucose levels. Inhibiting SGLT-1 reduces glucose and galactose absorption within the gastrointestinal tract and, to a lesser extent, also reduces glucose reabsorption within the kidney.
Lexicon will jointly commercialize and market sotagliflozin for type 1 diabetes with Sanofi after the two companies entered into an agreement in November 2015. Lexicon will retain full responsibility for clinical development and the option to co-promote sotagliflozin with Sanofi in the US. Sanofi is solely responsible for commercialization and marketing outside of the US.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.